Atrial fibrillation is a common heart rhythm disorder in which the upper chambers of the heart beat irregularly and often rapidly. It can reduce the heart's pumping efficiency and raise the risk of stroke and other complications.
Experts discuss balancing efficacy and safety in BTK inhibitor plus venetoclax combination therapy for CLL, including BTK lead-in strategies to reduce tumor lysis syndrome risk and the benefits of all-oral fixed-duration regimens.
Medtronic reported interim Affera Sphere-9 data showing 65.5% of VT patients were free from recurrence at six months. The FDA granted Breakthrough Device designation for Sphere-9 and approved a U.S. pivotal IDE.
A study found seniors with screening-detected atrial fibrillation had a roughly threefold higher risk of heart failure. Heart failure was often diagnosed within six months.
Wearable technologies are transforming clinical trials and healthcare with continuous monitoring capabilities, though clinical validation remains limited. While ECG features provide useful data for cardiac monitoring, many wearable metrics lack clinical accuracy and can cause patient anxiety. The technology shows promise for activity tracking and specific medical applications but requires cautious interpretation.
CRISPR Therapeutics reported a Q4 2025 loss of $1.37 per share, missing estimates, with revenues of $0.9 million falling short of expectations. The company's partner Vertex recorded $54 million in Casgevy sales for the quarter, with regulatory submissions for pediatric label expansion planned for early 2026.
New research shows patients on GLP-1 drugs may need to delay endoscopy procedures due to retained gastric contents, while a Cleveland Clinic study found 45% of obesity patients maintained weight loss one year after stopping the medications.
The phase 3 OCEANIC-STROKE trial of 12,327 patients showed asundexian, an oral Factor XIa inhibitor, reduced ischemic stroke recurrence by 26% when added to standard antiplatelet therapy, with no increase in major bleeding events.
Bristol Myers Squibb's growth portfolio increased 17% in 2025, partially offsetting a 15% decline in legacy products facing generic competition. The company's stock gained 11.4% in the past month on strong fourth-quarter results.
The FDA has approved the combination of acalabrutinib and venetoclax as the first all-oral, fixed-duration BTK inhibitor-based regimen for previously untreated adult patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.
Johnson & Johnson announced 12-month pilot-phase data from the OMNY-AF study showing 100% acute procedural success with zero adverse events in treating symptomatic paroxysmal atrial fibrillation across 30 patients.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07580937 |
Studying Heart Ablation After Left Atrial Closure in High-Bleeding-Risk Atrial Fibrillation Patients |
COMPLETED | |
| NCT07575867 |
CLOT-LESS - CLOsure Tailored: LEss Antithrombotic Strategy After LAAC for Stroke Prevention |
RECRUITING | |
| NCT07572253 |
A Study of Using CARTO SOUND™ FAM to Guide Pulsed Field Ablation for Atrial Fibrillation |
NOT_YET_RECRUITING | NA |
| NCT07570940 |
A Study Of Stellate Ganglion Blockade With Liposomal Bupivacaine In Preventing Atrial Fibrillation After Isolated Coronary Artery Bypass Grafting Surgery |
NOT_YET_RECRUITING | PHASE4 |
| NCT07569016 |
BIS-Guided Sedation Versus Standard Clinical Sedation During Elective Electrical Cardioversion for Atrial Fibrillation |
RECRUITING | NA |
| NCT07565337 |
The Application of Biomarkers in the Care of Patients With Atrial Fibrillation |
WITHDRAWN | |
| NCT07560644 |
Restoring Sinus Rhythm Using Dual-Shock Technique in Patients With Atrial Fibrillation |
NOT_YET_RECRUITING | PHASE2/PHASE3 |
| NCT07551947 |
Insulin Resistance as a Predictor of Pulsed Field Ablation Success in Atrial Fibrillation (HOMA-PULSE) |
ENROLLING_BY_INVITATION | |
| NCT07540065 |
AI-Assisted Workflow for Occult Atrial Fibrillation Detection After Ischemic Stroke: A Prospective Randomized Trial |
NOT_YET_RECRUITING | NA |
| NCT07527299 |
A Study of VARIPULSE Catheter in Participants With Persistent Atrial Fibrillation Undergoing Pulmonary Vein and Superior Vena Cava Isolation |
NOT_YET_RECRUITING | NA |
